BSX vs STE
BSX: Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties. STE: A premier provider of essential infection prevention, sterilization, and procedural care solutions for healthcare and life sciences organizations worldwide.
Side-by-side fundamentals
| Metric | BSX | STE | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $42.04 | $210.76 | |
| Market cap | $60.9B | $20.5B | |
| P/E as of 2026-10-08 | 17.05 | 26.55 | BSX lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 0.27 | n/a | |
| Net margin | +14.4% | +13.2% | BSX higher |
| Gross margin | +69.0% | +44.2% | BSX higher |
| Operating margin | +18.0% | +18.6% | STE higher |
| ROE | +11.8% | +10.9% | BSX higher |
| ROA | +6.6% | +7.3% | STE higher |
| Debt / equity as of 2026-09-03 | 0.51 | 0.27 | STE lower |
| Revenue growth (YoY) as of 2026-09-03 | +13.5% | +8.7% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | +9.4% | BSX higher |
| Dividend yield as of 2026-09-02 | n/a | +1.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 10 | STE higher |
| Beta as of 2026-09-03 | 0.57 | 0.50 | |
| 1-year return as of 2026-10-08 close | -56.6% | -13.0% | STE higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.